Published in Cancer Weekly, February 24th, 2004
Prior to the agreement, Jerini identified small-molecule lead series by applying its peptides-to-drugs approach. Jerini and Merck are joining forces to further develop Jerini's compounds.
Initiation of preclinical development is planned for 2005.
Under terms of the agreement, Jerini will receive an upfront payment, personnel funding, milestone payments, and royalties. Merck obtains worldwide rights for all indications in cancer, cardiovascular diseases, and diabetes and thyroid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.